Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab

Title:Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab

Volume: 18 Issue: 6

Author(s): Carlos A. Canas*, Fabio Bonilla-Abadia, Katherine Vallejo, Hector M. Rengifo, Marco A. Gallon and Gabriel J. Tobon

Affiliation:

• GIRAT: Grupo de investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional, Fundacion Valle del Lili and Universidad Icesi, Cali,Colombia

Keywords: Thyroid-associated ophthalmopathy, Graves` associated ophthalmopathy, tocilizumab, IL-6, extrathyroidal manifestation, infiltrating cytokines.

Abstract: Background and Objective: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6).

Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up.

Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor.

Conclusion: Tocilizumab could be an optional treatment in patients with TAO.

Cite this article as:

Canas A. Carlos *, Bonilla-Abadia Fabio , Vallejo Katherine , Rengifo M. Hector , Gallon A. Marco and Tobon J. Gabriel , Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab, Endocrine, Metabolic & Immune Disorders - Drug Targets 2018; 18 (6) . https://dx.doi.org/10.2174/1871530318666180702150243